The KATHERINE trial opened a new era wherein the treatment strategy of high-risk HER2-positive breast cancer has been renewed by escalating adjuvant therapy in patients with residual invasive disease after pre-surgical treatment. Here, ERBB2 is linked to breast carcinoma.